The Future of Esophageal Cancer Care: Tailoring Surgery and Chemoradiation with Precision Tools
The CROSS regimen led to a substantial improvement in overall survival, nearly doubling the median survival time.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Advances in targeted therapy for esophageal cancer
- A review of esophageal cancer research: emerging trends, progress and perspectives
- An esophageal cancer clinical trial - ES3
- Case Report: Small bowel metastasis from esophageal squamous cell carcinoma: a case series and systematic review of clinical characteristics, tropism, and survival outcomes
- Current landscape of immunotherapy in esophageal cancer: a literature review